Analystreport

CELYAD SA/ADR (NASDAQ: CYAD) had its "buy" rating re-affirmed by analysts at William Blair.

Celyad Oncology SA - American Depositary Shares  (CYAD) 
US:NASDAQ Investor Relations: celyad.com/en/investors